Baxter gets FDA nod for FEIBA as a prophylactic

Baxter (BAX -0.5%) gets another indication for the hemophilia treatment FEIBA.

The FDA has approved the drug for the prophylactic treatment of patients with hemophilia A or B who have developed inhibitors.

"This additional indication ... is aimed at reducing the number of bleeds among this patient population," the company's president of BioScience says. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs